ArticleDiseases & research2026
KLF2 Promotes Ellagic Acid-Mediated Osteogenic Differentiation of Dental Pulp-Derived Stem Cells via Autophagy and Mitochondrial Regulation.
Article in Diseases & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Backgrounds: Krüppel-like factor 2 (KLF2), a zinc-finger transcription factor of the Kruppel-like factor family, plays a crucial role in regulating various cellular processes, including differentiation, autophagy, and metabolism. However, it is not clear whether it has any role in the ellagic acid (EA)-mediated osteoblastic differentiation of dental pulp-derived stem cells (DPSCs). To investigate any regulatory role of KLF2 during EA-induced osteoblastic differentiation of DPSC, we have evaluated the path-ways emphasizing autophagy, mitophagy, and mitochondrial bioenergetics. Methods: We used induction and reduction of KLF2 approaches using chemical compounds, such as geranylgeranyl transferase inhibitor 298 (GGTI298), a known inducer of KLF2, and geranylgeranyl pyrophosphate (GGPP), a known inhibitor of KLF2. The key osteogenic, autophagy, and mitophagy markers were assessed via RT-qPCR and Western blotting, intracellular and mitochondrial ROS, along with mitochondrial membrane potential using high-resolution confocal microscopy, and cellular bioenergetics using Seahorse XF methods. Results: We found that EA alone significantly upregulated osteogenic markers, along with enhanced expression of autophagy and mitophagy-related molecules, and mitochondrial biogenetics. However, when we induced the KLF2, it amplified the expression of these markers and improved mitochondrial bioenergetics, suggesting a distinct relation between EA and KLF2. On the other hand, inhibition of KLF2 led to a significant downregulation of these markers. Conclusion: This supports the notion that KLF2 is a pivotal transcriptional regulator involved in mediating the pro-osteogenic effects of EA. It's activation enhanced autophagy, and improved mitochondrial bioenergetics, thereby facilitating EA-induced osteogenic differentiation of DPSCs. These findings refine our understanding of molecular mechanisms underlying polyphenol-mediated osteogenesis and show the pivotal role of KLF2 for regeneration via osteogenic differentiation of DPSCs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.